OmniAb, Inc. (OABI): Revenue

Annual figures by period end, from SEC filings.

$18.67M
Year ended 2025-12-31
$38.46M
Trailing 12 months to 2026-06-30
-31.9%
3-year compound annual growth
$59.08M2021-12-31: $34.75M2022-12-31: $59.08M2023-12-31: $34.16M2024-12-31: $26.39M2025-12-31: $18.67M$18.67M
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$18.67M-29.3%2026-03-04, From 2025-01-01
2024-12-31$26.39M-22.8%2026-03-04, From 2024-01-01
2023-12-31$34.16M-42.2%2025-03-18, From 2023-01-01
2022-12-31$59.08M+70.0%2024-03-25, From 2022-01-01
2021-12-31$34.75Mn/a2023-03-30, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
OmniAb, Inc. (OABI)2025-12-31$18.67M-29.3%
Foxo Technologies Inc. (FOXO)2025-12-31$16.37M+304.0%
MaxCyte, Inc. (MXCT)2025-12-31$33.03M-14.5%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$6.16M-34.2%
Absci Corp (ABSI)2025-12-31$2.80M-38.2%
NRC Health (NRC)2025-12-31$137.39M-4.0%
iSpecimen Inc. (ISPC)2025-12-31$1.93M-79.2%
OneMedNet Corp (ONMD)2025-12-31$1.36M+111.4%
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31$303.0K+21.8%

Compare OABI, FOXO, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗